587 F.Supp.3d 56
S.D.N.Y.2022Background
- Reckitt (a U.K. company) and its former subsidiary RBP/Indivior developed Suboxone Film as a replacement for Suboxone Tablets to blunt generic competition; both forms contain the same active ingredients.
- Plaintiffs allege Reckitt/RBP marketed the Film by falsely emphasizing pediatric-safety and lower abuse risk to coerce switches from Tablets, thereby preserving high-priced sales; Film generated substantial revenue (≈$2.9–3.0 billion 2010–2014).
- FDA initially questioned the Film’s asserted safety advantages; RBP withdrew Tablets and filed a citizen petition arguing safety concerns, which delayed generic entry and was later referred to the FTC.
- Government investigations culminated in Indivior/individual guilty pleas, an Indictment, and large civil/criminal resolutions; Reckitt announced charges related to DOJ/FTC investigations and took financial hits beginning in 2017–2019.
- Plaintiffs (public pension funds) sued under §10(b)/Rule 10b-5 (ADS purchasers) and, for one plaintiff (Pontiac) who bought LSE ordinary shares, under English law; defendants moved to dismiss for failure to plead fraud/particularity, lack of scienter, timeliness, and for arbitration/forum relief for Pontiac.
- The court sustained fraud claims (in part) as to statements that attributed Film’s success to patient/physician preference (against Thaxter, Kapoor, and Reckitt), dismissed many puffery/revenue-only statements and claims as to Bellamy and Hennah, dismissed Pontiac’s English-law counts for lack of pleaded reliance, and denied defendants’ truth-on-the-market and timeliness dismissal arguments.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Truth-on-the-market / timeliness | Market was unaware of the full scheme; corrective disclosures in 2017–2019 revealed concealed conduct and triggered claims within limitations | Public documents (NDAs, FDA letters, press reports) put market on notice earlier; claims are untimely or immaterial | Denied: court finds public info did not disclose the full scheme; timeliness is factual and not resolved at pleading stage |
| Material misstatements/omissions (reasons for Film’s success) | Statements attributing Film’s market strength to patient/physician preference omitted that success was driven by misleading marketing and anticompetitive tactics | Statements were truthful, general, or puffery; reported revenues were accurate and not actionable | Partially granted/denied: omissions actionable where management put reasons for success at issue (statements in ¶¶230,235,237,239,241,248,250 survive); pure revenue/puffery statements dismissed |
| Opinion/puffery defense | Many statements were opinions or corporate puffery not actionable | Plaintiffs: some opinions conveyed concrete market-reason assertions that rendered omissions misleading | Mixed: court applies Omnicare framework — some opinion/puffery dismissed, others (concrete claims about preference and causes of sales) survive |
| Scienter (individuals & corporation) | Allegations and later criminal proceedings, internal emails, and marketing directives show conscious misbehavior/recklessness by officers and company | Insufficient specific facts re knowledge for some individual defendants; alternative benign inferences exist | Plaintiffs plead scienter re Thaxter and Kapoor and hence Reckitt; scienter not pleaded as to Bellamy and Hennah (those claims dismissed) |
| Loss causation | Public disclosures/charges (2017–2019) corrected market and caused stock drops tied to defendants’ misconduct | Earlier public items already revealed the risks, so later drops not tied to concealed fraud | Denied: complaint adequately alleges corrective disclosures and price declines; defendants’ arguments are fact-intensive for later stages |
| Section 20(a) control-person liability | Individual defendants controlled Reckitt and are culpable participants | Thaxter was an RBP/Indivior officer (not Reckitt), and Bellamy/Hennah lack culpable participation evidence | Dismissed as to Bellamy and Hennah for lack of scienter/culpability; 20(a) claim dismissed as to Thaxter because no adequate allegation he controlled Reckitt |
| Pontiac’s English-law claims (arbitration/forum/reliance) | Pontiac: claims under English common law and FSMA; reliance can be inferred; U.S. forum acceptable | Reckitt points to articles of association requiring arbitration (Art.132) or English courts (Art.133); forum non conveniens/arbitration should dismiss or stay | Arbitration/forum motions denied (court finds Article 132 inapplicable); but Pontiac’s English-law counts (fraud, FSMA, negligent misrep.) dismissed for failure to plead that Pontiac knew of and relied on the alleged misrepresentations when purchasing shares |
Key Cases Cited
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (pleading must state plausible entitlement to relief; conclusory allegations disregarded)
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (complaint must plead factual content plausibly suggesting liability)
- Tellabs, Inc. v. Makor Issues & Rts., Ltd., 551 U.S. 308 (2007) (scienter inference evaluated holistically; must be at least as compelling as opposing inferences)
- Ganino v. Citizens Utils. Co., 228 F.3d 154 (2d Cir. 2000) (truth-on-the-market defense requires corrective information conveyed with sufficient intensity/credibility)
- Merck & Co. v. Reynolds, 559 U.S. 633 (2010) (statute of limitations in securities fraud accrues on discovery of facts constituting violation, including scienter)
- ATSI Commc’ns, Inc. v. Shaar Fund, Ltd., 493 F.3d 87 (2d Cir. 2007) (pleading rules and incorporation of documents into securities complaints)
- Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (2011) (omissions actionable when necessary to make existing statements not misleading)
- Omnicare, Inc. v. Laborers Dist. Council Const. Indus. Pension Fund, 575 U.S. 175 (2015) (opinion-statement liability: omission of facts can make an opinion misleading under certain circumstances)
- Set Capital LLC v. Credit Suisse Grp. AG, 996 F.3d 64 (2d Cir. 2021) (pleading scienter: courts must assess motive/opportunity and strong circumstantial evidence; evaluate allegations collectively)